Skip to main content
SpringerLink
Log in

C. difficile Microbiome Manipulation

  • Chapter
  • First Online:
Infection Prevention

  • 942 Accesses

Abstract

Clostridioides difficile infection (CDI) is a healthcare-associated infection with significant mortality, morbidity, and cost. Despite efforts by healthcare providers to adhere to infection prevention and control guidelines, CDI remains a significant cause of healthcare-associated infections. Antibiotic overuse, as well as its misuse, remains a significant contributor to CDIs and has also yet to be fully addressed. And since one of the risk factors for developing CDI is alteration of the microbiota of the gut by antimicrobials, manipulation of the human gut microbiome may be a reasonable strategy to prevent and control CDI. Probiotics, fecal microbiota transplantation, and purified bacterial therapeutics are potential approaches that utilize microbiome manipulation in the prevention and treatment of CDI.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. In: Healthcare cost and utilization project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality; 2012.

    Google Scholar 

  2. Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am. 2015;29(1):37–50.

    Article  PubMed  Google Scholar 

  3. Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, McDonald LC, Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. Burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320–30. https://doi.org/10.1056/NEJMoa1910215. PMID: 32242357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents. 2009;33:S33–6.

    Article  CAS  PubMed  Google Scholar 

  5. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370:1198–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis. 2016;16(1):447. https://doi.org/10.1186/s12879-016-1786-6. PMID: 27562241; PMCID: PMC5000548.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Barbut F. How to eradicate Clostridium difficile from the environment. J Hosp Infect. 2015;89(4):287–96.

    Article  CAS  PubMed  Google Scholar 

  8. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010;31(1):21–7.

    Article  PubMed  Google Scholar 

  9. Rebmann T, Carrico RM, Association for Professionals in Infection Control and Epidemiology. Preventing Clostridium difficile infections: an executive summary of the association for professionals in infection control and epidemiology’s elimination guide. Am J Infect Control. 2011;39(3):239–42.

    Article  PubMed  Google Scholar 

  10. Roberts K, Smith CF, Snelling AM, et al. Aerial dissemination of Clostridium difficile spores. BMC Infect Dis. 2008;8:7.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;29(1):37–50.

    Google Scholar 

  12. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013;6(4):295–308.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904.

    Article  CAS  PubMed  Google Scholar 

  14. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14.

    Article  CAS  Google Scholar 

  15. Bäckhed F, Fraser CM, Ringel Y, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. 2014;12(5):611–22.

    Article  CAS  Google Scholar 

  16. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146(6):1547–53.

    Article  CAS  PubMed  Google Scholar 

  17. Brandt LJ. Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol Hepatol. 2012;8(3):191–4.

    Google Scholar 

  18. Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol. 2015;69:445–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Agudelo-Ochoa GM, Valdés-Duque BE, Giraldo-Giraldo NA, Jaillier-Ramírez AM, Giraldo-Villa A, Acevedo-Castaño I, Yepes-Molina MA, Barbosa-Barbosa J, Benítez-Paéz A. Gut microbiota profiles in critically ill patients, potential biomarkers and risk variables for sepsis. Gut Microbes. 2020;12(1):1707610. https://doi.org/10.1080/19490976.2019.1707610. Epub 2020 Jan 10. PMID: 31924126; PMCID: PMC7524144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Schubert AM, Sinani H, Schloss PD. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. mBio. 2015;6:4.

    Article  CAS  Google Scholar 

  21. Skraban J, Dzeroski S, Zenko B, et al. Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS One. 2013;8(2):e58005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dreher-Lesnick S, et al. FDA developing improved methodology for determining purity of probiotic products. U.S. Food and Drug Administration, FDA. 2015. www.fda.gov/vaccines-blood-biologics/science-research-biologics/fda-developing-improved-methodology-determining-purity-probiotic-products.

  23. FAO/WHO Working Group on Drafting Guidelines for Evaluation of Probiotics in Food. Guidelines for evaluation of probiotics in food. May 2002.

    Google Scholar 

  24. Allen SJ. The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin North Am. 2015;29(1):135–44.

    Article  PubMed  Google Scholar 

  25. Hickson M, D’Souza AL, Muthu N, et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335:80–3.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of lactobacillus acidophilus CL1285 and lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105(7):1636–41.

    Article  PubMed  Google Scholar 

  27. Rafiq R. Prevention of Clostridium difficile (C. difficile) diarrhea with probiotic in hospitalized patients treated with antibiotics. Gastroenterology. 2007;132:A187.

    Google Scholar 

  28. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382(9900):1249–57.

    Article  PubMed  Google Scholar 

  29. McFarland LV. Probiotics for the primary and secondary prevention of C. difficile infections: a meta-analysis and systematic review. Antibiotics. 2015;4:160–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Beausoleil M, Fortier N, Guénette S, et al. Effect of a fermented milk combining lactobacillus acidophilus CL1285 and lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol. 2007;21(11):732–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ehrhardt S, Guo N, Hinz R, Schoppen S, May J, Reiser M, Schroeder MP, Schmiedel S, Keuchel M, Reisinger EC, Langeheinecke A, de Weerth A, Schuchmann M, Schaberg T, Ligges S, Eveslage M, Hagen RM, Burchard GD, Lohse AW. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis. 2016;3(1):ofw011. https://doi.org/10.1093/ofid/ofw011. PMID: 26973849; PMCID: PMC4785405.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095. https://doi.org/10.1002/14651858.CD006095.pub4. PMID: 29257353; PMCID: PMC6486212.

    Article  PubMed  Google Scholar 

  33. Lau CSM, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37.

    PubMed  PubMed Central  Google Scholar 

  34. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.

    Article  CAS  PubMed  Google Scholar 

  35. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48. https://doi.org/10.1093/cid/cix1085. PMID: 29462280; PMCID: PMC6018983.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–4.

    Article  CAS  PubMed  Google Scholar 

  37. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74(4):309–18.

    Article  CAS  PubMed  Google Scholar 

  38. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913–8.

    Article  CAS  PubMed  Google Scholar 

  39. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012–7.

    Article  CAS  PubMed  Google Scholar 

  40. Wullt M, Hagslätt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35(6–7):365–7. https://doi.org/10.1080/00365540310010985. PMID: 12953945.

    Article  PubMed  Google Scholar 

  41. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812–22.

    Article  PubMed  Google Scholar 

  42. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005;173(2):167–70.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;23(1):CD004611.

    Google Scholar 

  44. Barker AK, Duster M, Valentine S, Hess T, Archbald-Pannone L, Guerrant R, Safdar N. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J Antimicrob Chemother. 2017;72(11):3177–80. https://doi.org/10.1093/jac/dkx254. PMID: 28961980; PMCID: PMC5890711.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Auclair J, Frappier M, Millette M. Lactobacillus acidophilus CL1285, lactobacillus casei LBC80R, and lactobacillus rhamnosus CLR2 (bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clin Infect Dis. 2015;60:S135–43.

    Article  PubMed  Google Scholar 

  46. Schoster A, Kokotovic B, Permin A, Pedersen PD, Dal Bello F, Guardabassi L. In vitro inhibition of Clostridium difficile and clostridium perfringens by commercial probiotic strains. Anaerobe. 2013;20:36.

    Article  CAS  PubMed  Google Scholar 

  47. Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3):830S–7S.

    Article  CAS  PubMed  Google Scholar 

  48. Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract. 2012;2012:872716.

    Article  PubMed  PubMed Central  Google Scholar 

  49. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol. 2008;111:1–66.

    PubMed  Google Scholar 

  50. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol. 2005;3(5):442–8. https://doi.org/10.1016/s1542-3565(04)00677-9. PMID: 15880313.

    Article  CAS  PubMed  Google Scholar 

  51. Han DH. CP101 designated breakthrough Tx for recurrent C. difficile infection. MPR. 8 Feb 2019. www.empr.com/home/news/drugs-in-the-pipeline/cp101-designated-breakthrough-tx-for-recurrent-c-difficile-infection/#:~:text=CP101%20is%20an%20investigational%20oral,and%20help%20restore%20gut%20flora.

  52. Young A. Microbiome drug reduces recurrent CDI. Healio. 16 Oct 2020. www.healio.com/news/gastroenterology/20201016/microbiome-drug-reduces-recurrent-cdi.

  53. Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue Barriers. 2017;5(4):e1373208. https://doi.org/10.1080/21688370.2017.1373208. Epub 2017 Sep 28. PMID: 28956703; PMCID: PMC5788425.

  54. Rineh A, Kelso MJ, Vatansever F, Tegos GP, Hamblin MR. Clostridium difficile infection: molecular pathogenesis and novel therapeutics. Expert Rev Anti Infect Ther. 2014;12(1):131–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693–702.

    Article  PubMed  Google Scholar 

  56. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010;44(8):551–61.

    Article  PubMed  Google Scholar 

  57. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.

    Article  PubMed  CAS  Google Scholar 

  58. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–8.

    Article  PubMed  Google Scholar 

  59. Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479–93. https://doi.org/10.1111/apt.14201. Epub 2017 Jul 14. PMID: 28707337.

    Article  CAS  PubMed  Google Scholar 

  60. Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, Hvas CL. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;29–30:100642. https://doi.org/10.1016/j.eclinm.2020.100642. PMID: 33437951; PMCID: PMC7788438.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Bakken JS, Polgreen PM, Beekmann SE, Susan E, Riedo FX, Streit JA. Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe. 2013;24:20–4.

    Article  CAS  PubMed  Google Scholar 

  62. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772–8.

    Article  CAS  PubMed  Google Scholar 

  63. Burns DA, Heap JT, Minton NP. Clostridium difficile spore germination: an update. Res Microbiol. 2010;161(9):730–4.

    Article  PubMed  Google Scholar 

  64. Damman CJ, Miller SI, Surawicz CZ, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107(10):1452–9.

    Article  PubMed  Google Scholar 

  65. Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142–9. https://doi.org/10.1001/jama.2015.18098. PMID: 26757463.

    Article  CAS  PubMed  Google Scholar 

  66. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002.

    Article  PubMed  Google Scholar 

  67. Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, Reinert SE, Machan JT, Brandt LJ. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–16. https://doi.org/10.7326/M16-0271. Epub 2016 Aug 23. PMID: 27547925; PMCID: PMC5909820.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010;51(1):2–7.

    Article  PubMed  Google Scholar 

  69. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214:173–81.

    Article  PubMed  Google Scholar 

  70. Pierog A, Mencin A, Reilly NR. Fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Pediatr Infect Dis J. 2014;33(11):1198–200.

    Article  PubMed  Google Scholar 

  71. Walia R, Garg S, Song Y, et al. Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. J Pediatr Gastroenterol Nutr. 2014;59(5):565–70.

    Article  PubMed  Google Scholar 

  72. Nicholson MR, Mitchell PD, Alexander E, Ballal S, Bartlett M, Becker P, Davidovics Z, Docktor M, Dole M, Felix G, Gisser J, Hourigan SK, Jensen MK, Kaplan JL, Kelsen J, Kennedy M, Khanna S, Knackstedt E, Leier M, Lewis J, Lodarek A, Michail S, Oliva-Hemker M, Patton T, Queliza K, Russell GH, Singh N, Solomon A, Suskind DL, Werlin S, Kellermayer R, Kahn SA. Efficacy of fecal microbiota transplantation for Clostridium difficile infection in children. Clin Gastroenterol Hepatol. 2020;18(3):612–619.e1. https://doi.org/10.1016/j.cgh.2019.04.037. Epub 2019 Apr 19. PMID: 31009795; PMCID: PMC7549313.

    Article  PubMed  Google Scholar 

  73. Shogbesan O, Poudel DR, Victor S, Jehangir A, Fadahunsi O, Shogbesan G, Donato A. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol. 2018;2018:1394379. https://doi.org/10.1155/2018/1394379. PMID: 30246002; PMCID: PMC6139215.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Rubin MR, Bilezikian JP, Birken S, et al. Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol. 2008;159(4):469–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother. 2015;21(4):230–7.

    Article  PubMed  Google Scholar 

  76. Weingarden AR, Dosa PI, DeWinter E, et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS One. 2016;11(1):e0147210.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infection. J Infect Dis. 2013;207(10):1498–504.

    Article  CAS  PubMed  Google Scholar 

  78. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114.

    Article  PubMed  CAS  Google Scholar 

  79. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe. 2014;16(6):770–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51(9):2884–92.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Bakken JS, Borody T, Brandt LJ, et al. Perspective: treating Clostridium difficile infection with fecal microbiota. Clin Gastroenterol Hepatol. 2011;9:1044–9. https://doi.org/10.1016/j.cgh.2011.08.014.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A, European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569–80. https://doi.org/10.1136/gutjnl-2016-313017. Epub 2017 Jan 13. PMID: 28087657; PMCID: PMC5529972.

    Article  PubMed  Google Scholar 

  83. DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043–50. https://doi.org/10.1056/NEJMoa1910437. Epub 2019 Oct 30. PMID: 31665575. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.

    Article  PubMed  Google Scholar 

  84. Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun. 2012;80(11):3786–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Invest. 2014;124(10):4182–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Bangar H. Intestinal stem cell injury caused by Clostridium difficile is averted by Bacteroidales-induced crypt defenses. 2015.

    Google Scholar 

  87. Wortman JR, Lachey J, Lombardo M-J, et al. Design and evaluation of SER-262: a fermentation-derived microbiome therapeutic for the prevention of recurrence in patients with primary Clostridium difficile infection. Cambridge, MA: Seres Therapeutics; 2016.

    Google Scholar 

  88. Mullard A. Leading microbiome-based therapeutic falters in phase II trial. Nat Rev Drug Discov. 2016;15(9):595.

    PubMed  Google Scholar 

  89. Dieterle MG, Rao K, Young VB. Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Ann N Y Acad Sci. 2019;1435(1):110–38. https://doi.org/10.1111/nyas.13958. Epub 2018 Sep 21. PMID: 30238983; PMCID: PMC631245989.

    Article  PubMed  Google Scholar 

  90. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;8648(1):1156–60.

    Article  Google Scholar 

  91. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: “RePOOPulating” the gut. Microbiome. 2013;1(1):3.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA

    Jessica Penney, Jenna Wick, Tinzar Basein & Shira Doron

Authors
  1. Jessica Penney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jenna Wick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tinzar Basein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shira Doron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shira Doron .

Editor information

Editors and Affiliations

  1. VCUHS Epidemiology and Infection Control, Virginia Commonwealth University, Richmond, VA, USA

    Gonzalo Bearman

  2. Baltimore VA Medical Center, University of Maryland School of Medicine, Baltimore, MD, USA

    Daniel J. Morgan

  3. Division of Infectious Diseases, Cedars-Sinai, UCLA David Geffen School of Medicine, Los Angeles, CA, USA

    Rekha K. Murthy

  4. Infection Prevention and Control Department, University Health Network, Toronto, ON, Canada

    Susy Hota

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Penney, J., Wick, J., Basein, T., Doron, S. (2022). C. difficile Microbiome Manipulation. In: Bearman, G., Morgan, D.J., K. Murthy, R., Hota, S. (eds) Infection Prevention. Springer, Cham. https://doi.org/10.1007/978-3-030-98427-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98427-4_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-98426-7

  • Online ISBN: 978-3-030-98427-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation